RETRACTED: Systemic therapy in the management of metastatic or advanced salivary gland cancers (Oral Oncology (2012) 48(10) (948–957)(S1368837512001595)(10.1016/j.oraloncology.2012.05.004));Systemic therapy in the management of metastatic or advanced salivary gland cancers

Oral Oncology

Volumn 48, Issue 10, 2012, Pages 948-957

  Lagha, Aymen ^a   Chraiet, Nesrine ^a   Ayadi, Mouna ^a   Krimi, Sarra ^a   Allani, Bassem ^a   Rifi, Hela ^a   Raies, Henda ^a   Mezlini, Amel ^a  

^a SALAH AZAIEZ INSTITUTE   (Tunisia)

Author keywords

Adenocarcinoma; Adenocystic; Chemotherapy; Hormone therapy; Mucoepidermoid; Review; Salivary glands; Targeted therapy; Treatment

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTON AS2-1; BEVACIZUMAB; BLEOMYCIN; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; LAPATINIB; METHOTREXATE; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PEMETREXED; THALIDOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VELIMOGENE ALIPLASMID; VINCRISTINE; VINORELBINE DITARTRATE;

ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; DIARRHEA; DRUG DOSE INCREASE; DRUG MECHANISM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HORMONAL THERAPY; HUMAN; LEUKOPENIA; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SALIVARY GLAND CANCER; SKIN TOXICITY; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84866343854     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2018.01.034     Document Type: Erratum

References (97)

1. S.A. Laurie, and L. Licitra Systemic therapy in the palliative management of advanced salivary gland cancers J Clin Oncol 24 2006 2673 2678
2. M. Guzzo, L.D. Locati, and F.J. Prott Major and minor salivary gland tumors Crit Rev Oncol/Hematol 74 2010 134 148
3. Tumours of the salivary glands. In: Barnes L, Eveson JW, Reichart P, Sidransky D., editors. Pathology and genetics of head and neck tumours. World Health Organization, Lyon; 2005. p. 209.
4. M.W. Sung, K.H. Kim, and J.W. Kim Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck Arch Otolaryngol Head Neck Surg 129 2003 1193 1197
5. S.A. Laurie, A.L. Ho, and M.G. Fury Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review Lancet Oncol 12 2011 815 824
6. C.H. Terhaard, H. Lubsen, and I. Van der Tweel Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group Head Neck 26 2004 681 692
7. L. Licitra, S. Marchini, and S. Spinazze Cisplatin in advanced salivary gland carcinoma: a phase II study of 25 patients Cancer 68 1991 1874 1877
8. L.D. De Haan, P.H. De Mulder, and J.B. Vermorken Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck Head Neck 14 1992 273 277
9. D.E. Mattox, D. Von Hoff, and S.P. Balcerzak Southwest oncology group study of Mitoxantrone for the treatment of patients with advanced adenoid cystic carcinoma of the head and neck Invest New Drugs 8 1990 105 107
10. J. Verweii, P.M. de Mulder, and A. de Graeff Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and neck Cancer Cooperative Group Ann Oncol 7 1996 867 869
11. J.B. Vermorken, J. Verweij, and P.H. de Mulder Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC head and neck Cancer Cooperative Group Ann Oncol 4 1993 785 788
12. J.Y. Suen, and M.E. Johns Chemotherapy for salivary gland cancer Laryngoscope 92 1982 235 239
13. M.J. Kaplan, M.E. Johns, and R.W. Cantrell Chemotherapy for salivary gland cancer Otolaryngol Head Neck Surg 95 1986 165 170
14. M. Airoldi, F. Pedani, and G. Succo Phase II randomised trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies Cancer 91 2001 541 547
15. A.S.D. Spiers, D.L.W. Esseltine, J.C. Ruckdeschel, J.N.P. Davies, and J. Horton Metastatic adenoid cystic carcinoma of salivary glands: case reports and review of literature Cancer Control 3 4 1996 336 342
16. I.F. Tannock, and D.J. Sutherland Chemotherapy for adenocystic carcinoma Cancer 46 1980 452 454
17. J. Gilbert, Y. Li, and H.A. Pinto Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group Head Neck 28 2006 197 204
18. J. Raguse, H.J. Gath, J. Bier, H. Riess, and H. Oettle Docetaxel (taxotere) in recurrent high grade mucoepidermoid carcinoma of the major salivary glands Oral Oncol Extra 40 2004 5 7
19. F. Belli, L. Di Lauro, A. Zappanico, and S. Giunta Docetaxel in the treatment of metastatic carcinoma of the salivary glands report of a case Clin Ter 150 1 1999 77 79
20. C.M. Van Herpen, L.D. Locati, and J. Buter Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982) Eur J Cancer 44 2008 2542 2545
21. D.S. Alberts, M.R. Manning, and S.W. Coulthared Adriamycin/cis-platinum/ cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland Cancer 47 1981 645 648
22. A.I. Dreyfuss, J.R. Clark, and B.G. Fallon Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin Cancer 60 1987 2869 2872
23. C.P. Belani, M.A. Eisenberger, and W.C. Gray Preliminary experience with chemotherapy in advanced salivary gland neoplasms Med Pediatr Oncol 16 1988 197 202
24. E.T. Creagan, J.E. Woods, and J. Rubin Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck Cancer 62 1988 2313 2319
25. L. Licitra, R. Cavina, and C. Grandi Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma: a phase II trial of 22 patients Ann Oncol 7 1996 640 642
26. M.A. Eisenberger Supporting evidence for an active treatment program for advanced salivary gland carcinoma Cancer Treat Rep 69 1985 319 321
27. A.P. Venook, A. Tseng Jr, and F.J. Meyers Cisplatin, doxorubicin and 5-fluoruracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group J Clin Oncol 5 1987 951 955
28. I.W. Dimery, S.S. Legha, and L. Shirinian Fluorouracil, doxorubicin, cyclophosphamide and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma J Clin Oncol 8 1990 1056 1062
29. M. Airoldi, F. Pedani, and V. Brando Cisplatin, epirubicin anf 5-fluouracil combination chemotherapy for recurrent carcinoma of the salivary gland Tumori 75 1989 252 256
30. P.J. Ross, E.M. Teoh, and R.P. A'Hern Epirubicin, cisplatin and protacted venous infusion 5-fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma Clin Oncol (R Coll Radiol) 21 2009 311 314
31. M. Tsukuda, T. Kokatsu, and K. Ito Chemotherapy for recurrent adeno and adenoidcystic carcinomas in the head and neck J Cancer Res Clin Oncol 119 1993 756 758
32. M.R. Posner, T.J. Ervin, and R.R. Weichselbaum Chemotherapy for advanced salivary gland neoplasms Cancer 50 1982 2261 2264
33. P.L. Triozzi, A. Brantley, and S. Fisher 5-Fluoruracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck Cancer 59 1987 887 890
34. M.E. Hill, D.O. Constenla, and R.P. A'Hern Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma Oral Oncol 33 1997 275 278
35. M. Airoldi, G. Fornari, and F. Fedani Paclitaxel and carboplatin for recurrent salivary gland malignancies Anticancer Res 20 2000 3781 3783
36. J.C. Ruzich, M.C. Ciesla, and J.L. Clark Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report Head Neck 24 2002 406 410
37. C. Gedlicka, B. Schull, and M. Formanek Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies Anticancer Drugs 13 2002 491 495
38. S.A. Laurie, L.L. Siu, and E. Winquist A phase II study of platinium and gemcitabine in advanced salivary gland cancers: a trial of the NCIC clinical trials group Cancer 116 2010 362 368
39. A.S. Jones, D.E. Phillips, J.A. Cook, and T.R. Helliwell A randomized phase II trial of Epirubicin and 5-Fluorouracil versus Cisplatinum in the palliation of advanced and recurrent malignant tumor of the salivary glands Br J Cancer 67 1993 112 114
40. F. Pedani, M. Airoldi, S. Marchionatti, and C. Bumma Cisplatin + irinotecan in recurrent/metastatic salivary gland malignancies Eur J Cancer 1 Suppl. 5 2003 S44 [9]
41. M. Mino, B.Z. Pilch, and W.C. Faquin Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma Mod Pathol 16 12 2003 1224 1231
42. R.L. Dodd, and N.J. Slevin Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies Oral Oncol 42 2006 759 769
43. V.A. Holst, C.E. Marshall, and C.A. Moskaluk Kit protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma Mod Pathol 12 1999 956 960
44. Y.M. Jeng, C.Y. Lin, and H.C. Hsu Expression of the c-kit protein is associated with certain sub-types of salivary gland carcinoma Cancer Lett 154 2000 107 111
45. P.C. Edwards, T. Bhuiya, and R.D. Kelsch C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 5 2003 586 593
46. C.R. Penner, A.L. Folpe, and S.D. Budnick C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma Mod Pathol 15 7 2002 687 691
47. A.M. Oliveira, J.L. Hornick, A. Duensing, F. Medeiros, C.D.M. Fletcher, and J.A. Fletcher KIT expression and activation in adenoid cystic carcinoma [abstract] Mod Pathol 16 2003 221A
48. J.M. Guigay, F. Bidault, S. Temam, F. Janot, E. Raymond, and S. Faivre Antitumor activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: a phase II study Proc Am Soc Clin Oncol 25 2007 [abstr 6086]
49. N.J. Slevin, K.L. Mais, and I. Bruce Imatinib with cisplatin in recurrent and/or metastatic adenoidcystic carcinoma-preliminary results of a phase II study of 18 patients with response assessed by morphological and functional imaging Eur J Cancer Suppl 3 2005 292 293
50. H.J. Ochel, G. Gademann, C. Rocken, and H. Wordehoff Effects of imatinib mesylate on adenoid cystic carcinomas Anticancer Res 25 2005 3659 3664
51. C.H. Lin, R.F. Yen, Y.M. Jeng, C.Y. Tzen, C. Hsu, and R.L. Hong Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate Head Neck 27 2005 1022 1027
52. S.J. Hotte, E.W. Winquist, and E. Lamont Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study J Clin Oncol 23 2005 585 590
53. M.R. Pfeffer, Y. Talmi, R. Catane, Z. Symon, A. Yosepovitch, and M. Levitt A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands Oral Oncol 43 2007 33 36
54. J.C. Alcedo, J.M. Fabrega, and J.R. Arosemena Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases Head Neck 26 2004 829 831
55. S. Faivre, E. Raymond, and O. Casiraghi J Clin Oncol 23 2005 6271 6273 [author reply 6273-6274]
56. M. Vered, E. Braunstein, and A. Buchner Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin Head Neck 24 2002 632 636
57. B. Glisson, G. Blumenschein, and H. Francisco Phase II trial of gefitinib in patients with incurable salivary gland cancer Proc Am Soc, Clin Oncol 23 2005 [abstr 5532]
58. M. Agulnik, E.W. Cohen, and R.B. Cohen Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and nonadenoid cystic carcinoma malignant tumors of the salivary glands J Clin Oncol 25 25 2007 3978 3984
59. L.D. Locati, P. Bossi, and F. Perrone Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study Oral Oncol 45 2009 574 578
60. C. Giannoni, A.K. El-Naggar, N.G. Ordnoez, Z.N. Tu, J. Austin, and M.A. Luna C-erbB-2/neu oncogene and Ki67 analysis in the assessment of palatal salivary gland neoplasms Otolaryngol Head Neck Surg 112 1995 391 398
61. S. Shintani, T. Funayama, Y. Yoshihama, R.E. Alcalde, K. Ootsuki, and N. Terakado Expression of C-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study Anticancer Res 15 1995 2623 2626
62. A.J. Khan, M.P. Digiovanna, D.A. Ross, C.T. Sasaki, D. Carter, and Y.H. Son Adenoid cystic carcinoma: a retrospective clinical review Int J Cancer 96 2001 149 158
63. B. Glisson, A.D. Colevas, and R. Haddad HER2 expression in salivary gland carcinomas: dependence on histological subtype Clin Cancer Res 10 3 2004 944 946
64. S. Dori, M. Vered, and R. David HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study J Oral Pathol Med 31 2002 463 467
65. K.J. Cho, S.S. Lee, and Y.S. Lee Proliferating cell nuclear antigen and C-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands Head Neck 21 1999 414 419
66. V. Karja, S. Syrjanen, V. Kataja, and K. Syrjanen C-erbB-2 oncogene expression in salivary gland tumours ORL J Otorhinolaryngol Relat Spec 56 4 1994 206 212
67. N.M. Kerhonan, K. Blessing, G. King, I.P. Corbett, and I.D. Miller Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study J Pathol 163 1 1991 77 80
68. S. Sugano, K. Mukai, H. Tsuda, S. Hirohashi, S. Furuya, and Y. Shimosato Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness Laryngoscope 102 8 1992 923 927
69. K. Kusafuka Expressions of oncogene products in adenoid cystic carcinomas of salivary glands: immunohistochemical study Kobubyo Gakkai Zasshi 58 4 1991 696 717
70. M.F. Press, M.C. Pike, and G. Hung Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis Cancer Res 54 21 1994 5675 5682
71. D.T. Weed, C. Gomez-Fernandez, and J. Pacheco MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma Head Neck 26 4 2004 353 364
72. M.D. Gibbons, U. Manne, W.R. Carroll, G.E. Peters, H.L. Weiss, and W.E. Grizzle Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands Laryngoscope 111 8 2001 1373 1378
73. P. Shrestha, J.W. Huang, T. Tsuji, F. Shinozaki, K. Maeda, and K. Sasaki Rare expression of the c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study J Oral Pathol Med 21 1992 477 480
74. M. Jaehne, K. Roeser, and T. Jaekel Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases Cancer 103 12 2005 2526 2533
75. V. Nabili, J.W. Tan, and S. Bhuta Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy Head Neck 29 10 2007 907 912
76. R. Haddad, A.D. Colevas, and J.F. Krane Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study Oral Oncol 39 7 2003 724 727
77. A. Prat, M. Parera, and V. Reyes Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy Head Neck 30 5 2008 680 683
78. M. Nashed, and R.J. Casasola Biological therapy of salivary duct carcinoma J Laryngol Otol 123 2 2009 250 252
79. O. Kaidar-Person, S. Billan, and A. Kuten Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review Med Oncol March 6 2011
80. J. Zhang, B. Peng, and X. Chen Expressions of nuclear factor kappa B, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome Clin Cancer Res 11 20 2005 7334 7343
81. J. Zhang, and B. Peng NF-kappaB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro Cell Prolif 42 2009 150 161
82. A. Argiris, M. Ghebremichael, and B. Burtness A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303) Cancer 117 2011 3374 3382
83. S. Dori, P. Trougouboff, R. David, and A. Buchner Immunohistochemical evaluation of estrogen and progesterone receptors in adenoid cystic carcinoma of salivary gland origin Oral Oncol 36 2000 450 453
84. A.S. Miller, G.G. Hartman, S.Y. Chen, P.R. Edmonds, S.A. Brightman, and R.D. Harwick Estrogen receptor assay in polymorphous lowgrade adenocarcinoma and adenoid cystic carcinoma of salivary gland origin. An immunohistochemical study Oral Surg Oral Med Oral Pathol 77 1 1994 36 40
85. E.V. Gaffney, J.A. Pinkston, and J.J. Eidson Estrogen receptors in parotid tumors Endocr Res 21 1995 635 643
86. F.R. Pires, D.E. Perez, O.P. Almeida, and L.P. Kowalski Estrogen receptor expression in salivary gland mucoepidermoid carcinoma and adenoid cystic carcinoma Pathol Oncol Res 10 3 2004 166 168
87. I.W. Dimery, L.A. Jones, R.P. Verjan, A.K. Raymond, H. Goepfert, and W.K. Hong Estrogen receptors in normal salivary gland and salivary gland carcinoma Arch Otolaryngol Head Neck Surg 113 1987 1082 1085
88. P.C. Shick, G.P. Riordan, and R.D. Foss Estrogen and progesterone receptors in salivary gland adenoid cystic carcinoma Oral Surg Oral Med Oral Pathol Oral Radiol Endod 80 4 1995 440 444
89. J.P. Jeannon, J.V. Soames, H. Bell, and J.A. Wilson Immunohistochemical detection of oestrogen and progesterone receptors in human salivary gland tumours Clin Otolaryngol 24 1 1999 52 54
90. S. Ozono, M. Onozuka, K. Sato, and Y. Ito Immunohistochemical localization of estradiol, progesterone, and progesterone receptor in human salivary glands and salivary adenoid cystic carcinomas Cell Struct Funct 17 1992 169 175
91. C.Y. Fan, M.F. Melhem, and A.S. Hosal Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma Arch Otolaryngol Head Neck Surg 127 9 2001 1075 1079
92. A. Shadaba, M.N. Gaze, and H.R. Grant The response of adenoid cystic carcinoma to tamoxifen J Laryngol 111 12 1997 1186 1189
93. A.D. Elkin, and C.D. Jacobs Tamoxifen for salivary gland adenoid cystic carcinoma: a report of two cases J Cancer Res Clin Oncol 134 2008 1151 1153
94. L.D. Locati, P. Quattrone, and P. Bossi A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland Ann Oncol 14 8 2003 1327 1328
95. R.W. Van der Hulst, J.H. Van Krieken, and T.H. Van der Kwast Partial remission of parotid gland carcinoma after goserelin Lancet 344 1994 817
96. http://www.clinicaltrials.gov.
97. V.L. Schramm Jr, C. Scrodes, and E.N. Myers Cisplatin therapy for adenoid cystic carcinoma Arch Otolaryngol 107 1981 739 741